Camber Capital Management’s Gilead Sciences GILD Stock Holding History

Camber Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,500,000	Closed	-$105M	–	41
2021 Q3	$105M	Buy	1,500,000 +500,000	+50%	+$35.1M	3.23%	13
2021 Q2	$68.9M	Buy	+1,000,000	New	+$66.8M	2.32%	20
2021 Q1	–	Sell	-2,500,000	Closed	-$146M	–	39
2020 Q4	$146M	Buy	+2,500,000	New	+$151M	5.11%	5
2017 Q3	–	Sell	-2,000,000	Closed	-$142M	–	25
2017 Q2	$142M	Buy	2,000,000 +1,000,000	+100%	+$66.5M	6.89%	4
2017 Q1	$67.9M	Hold	1,000,000	–	–	2.75%	11
2016 Q4	$71.6M	Hold	1,000,000	–	–	3.73%	10
2016 Q3	$79.1M	Hold	1,000,000	–	–	3.48%	9
2016 Q2	$83.4M	Buy	1,000,000 +500,000	+100%	+$44.4M	4.03%	4
2016 Q1	$45.9M	Buy	+500,000	New	+$45.1M	2.69%	16

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Camber Capital Management's GILD Position: Q2 2022 in Review

Camber Capital Management sold out of Gilead Sciences (GILD) in Q2 2022, closing a stake of 2,500,000 shares — an estimated $149M sold.

Camber Capital Management first reported a position in GILD in Q2 2016 and held it in 13 quarters. The position peaked at $163M in Q4 2021. 1,604 funds tracked by Wall St. Rank hold GILD as of Q2 2022.

Camber Capital Management reported no remaining Gilead Sciences position as of Q2 2022 after selling out during the quarter.
Camber Capital Management sold 2,500,000 Gilead Sciences shares in Q2 2022, an estimated $149M.
Camber Capital Management first reported a position in Gilead Sciences in Q2 2016 and held it in 13 quarters.
Camber Capital Management's Gilead Sciences position peaked at $163M in Q4 2021.
1,604 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2022.

Based on Camber Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.